NON-HODGKIN'S LYMPHOMA

This study tests whether adding the drug acalabrutinib to standard chemotherapy can cure more people with untreated diffuse large B-cell lymphoma, an aggressive blood cancer. About 132 adults will take the pill twice daily for up to 14 days, then receive standard chemo and rituxi…

This early-stage study tests an experimental drug called ABBV 291 in adults with Non-Hodgkin's lymphoma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 165 partici…

This study tests a new way to make immune cells (T cells) that can attack cancer cells infected with the Epstein-Barr virus (EBV). The cells are grown faster in the lab and given to patients with Hodgkin or non-Hodgkin lymphoma, or related diseases that have come back or not gone…

This study tests a new drug called GNC-035 for people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is a special antibody designed to attack cancer cells from multiple angles. The trial has two parts: first, finding the safest dose, and…

This study tests an improved method for cord blood transplants in adults with hard-to-treat blood cancers like leukemia and lymphoma. The approach uses a standard set of steps—including chemotherapy, radiation, and careful follow-up—to help the body accept the new stem cells. Res…

This study tests whether a combination of three drugs (etoposide, cytarabine, and PEG-rhG-CSF) works better than standard chemotherapy for collecting stem cells in people with non-Hodgkin's lymphoma who need a stem cell transplant. About 99 participants will be randomly assigned …

This early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study tests a new drug called GNC-038, a special antibody that targets cancer from four different angles. It is for people with Non-Hodgkin's lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find …

This study compares two common treatments—immunoglobulin and antibiotics—to see which is better at preventing serious infections in people with blood cancers like myeloma, lymphoma, or leukemia. About 900 adults will take part. The goal is to find the safest and most effective wa…

This study aims to understand why some families have more than one person with lymphoma or related blood cancers. Researchers will collect tumor samples and genetic information from 1,500 participants to look for inherited gene changes that raise cancer risk. No treatment is give…

This study is gathering basic health and survival information from 2000 people who are getting a stem cell transplant for blood cancers or immune diseases. The goal is to build a database that doctors can use to improve care and answer future questions. No experimental treatments…

This study is a large registry that gathers medical information and biological samples from 10,000 adults with acute lymphoblastic leukemia (ALL) and similar blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time, in order to improve …

This study is collecting standardized medical data from 2,000 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The goal is to create a new prognostic index that helps doctors identify which patients are at higher or lower risk, so they can t…